The Global Viral Vector & Plasmid DNA Manufacturing Market is estimated to grow at CAGR above 21.4 % over the forecast time frame 2019-2026 and reach the market value around USD 1.8 billion by 2026.
The market for viral vector & plasmid DNA in the forecast period should be increased by the prevalence and incidence of genetic disorders, infectious diseases, and cancer high unmet needs of rare disorders patients and increasing acceptability of relatively newer treatment alternatives in emerging economies. According to Cancer Research UK, there were 17 million new cases of breast, lung, bowel, prostate cancer in 2018 and four most common cancers in the world, accounting for about 43% of new cases.
In the application of gene therapy, viral vector and plasmid DNA production is used to diagnose patients and treat diseases. High cancer prevalence is projected to boost demand for gene therapy, which will in turn drive market growth. In 2012, cancer is the world’s second largest source of morbidity and death, with around 14 million new cases reported in 2012 and 8.8 million deaths reported in 2015 around the world. In addition, WHO stated that by the end of 2030, the number of new cancer cases should increase by about 70 %
In addition, increased research and development activities in the field of the manufacture of viral vectors and plasmid DNA will in the near future boost its demand. In April 2017, for example, Transgene announced plans for the launch of the research collaboration on TG4010 as an advanced non-scrooky, not-small cell lung cancer (NSCLC) treatment for patients with standard chemical therapy (SCT) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab).
Plasmid DNA is a very attractive part of the global manufacturing market for viral vectors and plasmid DNAs, which is followed by Adeno Associated Viruses (AAV). This is due to the extensive use in the manufacture of various viral vectors of plasmid DNA as the raw material. In addition to the conventional vaccines, various studies have highlighted the benefits of DNA-based vaccines. Due to the various benefits offered by AAV over other vectors, the Adeno-associated Virus segment is likely to enlarge in a significant CAGR over the forecast time period, making them the vector of choice for different clinical studies.
The key manufacturer in this market are CobraBiologics, Novasep, Spark Therapeutics, Inc., FUJIFILM Diosynth Ltd, Cell and Gene Therapy Catapult, Kaneka Eurogentec, Inc. Merck KGaA, Lonza and UniQure N.V. and others.
For More Information, Visit@ https://www.acumenresearchandconsulting.com/request-sample/1335
20+ years of diverse and extensive experience in higher education including teaching, research, and university and community service in overseas universities and colleges.
Associate Editor, and publications in international refereed journals and presented most of them in international conferences in the fields of Applied Multivariate Statistics, Mortality, Social Science, Economics.